secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001193125-24-195397
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Voranigo; Royalty Pharma pays $905M milestone, expects >$150M/yr royalties
--------------------------------------------------------------------------------

- FDA approved Voranigo (vorasidenib) for IDH1/2 mutant diffuse glioma on August 6, 2024.
- Royalty Pharma pays $905M to Agios upon approval under May 2024 royalty agreement.
- Royalty Pharma receives 15% royalty on U.S. net sales up to $1B, 12% above $1B.
- Peak annual sales projected >$1B; annual royalties >$150M through 2038.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000119312524195397/0001193125-24-195397-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000119312524195397/d868175d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-195397

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer